Skip to main content
. Author manuscript; available in PMC: 2011 Feb 3.
Published in final edited form as: Vaccine. 2009 Nov 24;28(5):1363. doi: 10.1016/j.vaccine.2009.11.005

Figure 2.

Figure 2

Treatment with Cox-2 inhibitors early in the VV infection fails to blunt VV-specific B cell antibody production. C57Bl/6 mice (n = 4) were administered vehicle, SC-58125 (5 mg/kg) or NS-398 (10 mg/kg) at the onset of infection and ending on day 6 (3 doses). Plasma titers of VV-specific IgM (A & B) and IgG (C & D) was determined by ELISA on day 14 and 28. The number of VV-specific antibody secreting cells were assessed by ELISPOTs performed on day 14 (E) and day 28 (F) for all antibody isotypes. Data are represented as mean ± SEM, * p <0.05.

HHS Vulnerability Disclosure